"The research collaboration will investigate the ability of investigational compound PBT434 to mitigate gastrointestinal dysfunction; constipation, lowered colon motility and inflammation in mouse models, including an alpha-synuclein transgenic mouse."
Will that be the subject of Prana's orphan drug designation for Parkinson's? Nothing in the release indicates structure of the designation of responsibilities of Takeda and Prana Biotech. Who does what, and who will fund what, and how much investigation is needed for this new PD "diagnosis" as PBT434 remains preclinical? Appears that Phase I is still planned for later this year. It would be good to hear something from Takeda.
Takeda announced on June 29 their filing of a new drug application for Teva's PD drug rasagiline mesylate. Teva is Dr. Stamler's former employer.
PBT Price at posting:
5.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)